Cargando…
Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease
Vogt-Koyanagi-Harada disease (VKH) is an important refractory uveitis mediated by pathological T cells (TCs). Tofacitinib (TOFA) is a JAK- targeted therapy for several autoimmune diseases. However, the specific pathogenesis and targeted therapeutics for VKH remain largely unknown. Based on single-ce...
Autores principales: | Liu, Xiuxing, Jiang, Qi, Lv, Jianjie, Yang, Shizhao, Huang, Zhaohao, Duan, Runping, Tao, Tianyu, Li, Zhaohuai, Ju, Rong, Zheng, Yingfeng, Su, Wenru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746911/ https://www.ncbi.nlm.nih.gov/pubmed/36301664 http://dx.doi.org/10.1172/jci.insight.162335 |
Ejemplares similares
-
Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy
por: Yang, Shizhao, et al.
Publicado: (2022) -
Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients
por: Yang, Shizhao, et al.
Publicado: (2022) -
Tofacitinib in Vogt-Koyanagi-Harada disease
por: Dutta Majumder, Parthopratim, et al.
Publicado: (2020) -
Treatment of Vogt-Koyanagi-Harada Disease
por: Alaql, Musab K, et al.
Publicado: (2020) -
An Unusual Presentation of Vogt–Koyanagi–Harada
por: Ipek, Sefik Can, et al.
Publicado: (2021)